Q3 EPS Estimates for TScan Therapeutics Decreased by Wedbush

Key Points

• Wedbush has cut its Q3 2025 earnings per share estimate for TScan Therapeutics to ($0.29), down from a prior estimate of ($0.27), while maintaining an "Outperform" rating and a price target of $7.00.
• The company's latest quarterly earnings report showed a loss of ($0.28) per share, matching analyst expectations, with revenues of $3.08 million, significantly surpassing consensus estimates.
• Institutional investors own approximately 82.83% of TScan Therapeutics, indicating strong backing from major financial players.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Analysts at Wedbush reduced their Q3 2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.29) per share for the quarter, down from their prior forecast of ($0.27). Wedbush currently has a "Outperform" rating and a $7.00 target price on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics' Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.04) EPS, Q1 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($0.97) EPS and FY2028 earnings at ($0.91) EPS.

A number of other brokerages have also recently issued reports on TCRX. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. HC Wainwright reduced their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, TScan Therapeutics currently has an average rating of "Buy" and a consensus price target of $7.80.

TScan Therapeutics Stock Performance

TCRX traded up $0.0450 on Friday, reaching $1.7250. The company had a trading volume of 100,642 shares, compared to its average volume of 464,879. The stock has a market cap of $97.62 million, a P/E ratio of -1.58 and a beta of 0.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.2250. The company's fifty day moving average is $1.68 and its 200 day moving average is $1.65.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, hitting analysts' consensus estimates of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The firm had revenue of $3.08 million during the quarter, compared to analysts' expectations of $1.31 million.

Institutional Trading of TScan Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TCRX. ProShare Advisors LLC bought a new position in TScan Therapeutics in the fourth quarter valued at approximately $40,000. Catalyst Funds Management Pty Ltd bought a new position in shares of TScan Therapeutics in the 2nd quarter valued at $26,000. Squarepoint Ops LLC bought a new position in shares of TScan Therapeutics in the 4th quarter valued at $59,000. Wells Fargo & Company MN lifted its position in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after buying an additional 5,694 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in TScan Therapeutics in the second quarter valued at about $29,000. Institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.